Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 7, 2002

View Archived Issues

Effective neuroprotection provided by new redox metabolic modulator

Neuroprotective estrogen analogue lacking hormonal effects characterized at Stroke conference

Cytokine-based gene therapy of brain ischemia promising according to Japanese research

Experiments link aromatase to neuroprotection in cerebral ischemia

Sildenafil demonstrates beneficial activity in rat model of cerebral ischemia

Glyceryl trinitrate reduces hypertension in stroke patients

Study finds oral contraceptives double the risk of first ischemic stroke

MEK1/2 inhibitor provides neuroprotection in cerebral ischemic injury

Xopenex approved for pediatric use in bronchospasm

Neurocrine updates clinical program progress in 2001

Gilead announces 2001 product highlights

Chlorambucil in the treatment of sight-threatening ocular inflammation

MCA approves phase II study of TTS in pancreatic cancer

CT-2106 cleared to enter phase I clinical testing

Encouraging results observed in phase IIa trial of AOD-9604 in obese patients

Novel dual gene therapy as a treatment for heart disease

Idun selects lead candidate for cardiovascular program

Sakai to codevelop and market Theratechnologies' ThGRF peptide in Japan

Amidine derivatives synthesized for neurological and neurodegenerative disorders

Takeda describes compounds for hyperlipidemia in recent patent

Merck discloses preparation and use of pyridine derivatives in CNS disorders

Nociceptin antagonists in the Banyu pipeline

New series from Taisho inhibits 20-HETE production

Acetylcholinesterase inhibitors described by Eisai for cognition disorders

Vitamin D analogues for the treatment of dermatoses

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...